Biotricity Q2 FY2026 revenue up 19% to $3.9M; net loss narrows 53% to $0.77M

BIOTRICITY INC.

2026-Q2 EPS reported -$0.06 revenue$7,759,788

Revenue $3.9M (+19% YoY); gross margin 81.9% vs 75.3% prior year.
Net loss $0.77M ($0.03/sh) vs $1.7M ($0.07/sh), a 53% improvement.
Recurring TaaS technology fees $3.5M, 88.7% of total revenue.
Regulatory progress in Canada, Saudi Arabia, and Argentina; GPOs covering 90% of U.S. hospitals.
CEO cites AI-driven automation and Biocore Pro adoption as growth drivers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.